Detalhe da pesquisa
1.
High response rate to PD-1 blockade in desmoplastic melanomas.
Nature
; 553(7688): 347-350, 2018 01 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-29320474
2.
NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2021.
J Natl Compr Canc Netw
; 19(4): 364-376, 2021 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33845460
3.
Patient-reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma.
BJU Int
; 126(1): 73-82, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32233107
4.
NCCN Guidelines Insights: Uveal Melanoma, Version 1.2019.
J Natl Compr Canc Netw
; 18(2): 120-131, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32023525
5.
Health-related quality of life (QoL) in patients with advanced melanoma receiving immunotherapies in real-world clinical practice settings.
Qual Life Res
; 29(10): 2651-2660, 2020 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-32405921
6.
Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 17(4): 367-402, 2019 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30959471
7.
NCCTG N0879 (Alliance): A randomized phase 2 cooperative group trial of carboplatin, paclitaxel, and bevacizumab ± everolimus for metastatic melanoma.
Cancer
; 124(3): 537-545, 2018 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29044496
8.
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.
Lancet
; 389(10064): 67-76, 2017 01 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-27939400
9.
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.
Lancet
; 387(10031): 1909-20, 2016 May 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-26952546
10.
BAP1 and PBRM1 in metastatic clear cell renal cell carcinoma: tumor heterogeneity and concordance with paired primary tumor.
BMC Urol
; 17(1): 19, 2017 Mar 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-28327121
11.
Non-clear cell renal cell carcinomas: biological insights and therapeutic challenges and opportunities.
Clin Adv Hematol Oncol
; 15(5): 409-418, 2017 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-28591094
12.
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.
N Engl J Med
; 369(2): 134-44, 2013 Jul 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-23724846
13.
Loss of histone H3 lysine 36 trimethylation is associated with an increased risk of renal cell carcinoma-specific death.
Mod Pathol
; 29(1): 34-42, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26516698
14.
Detection of tumor-associated cells in cryopreserved peripheral blood mononuclear cell samples for retrospective analysis.
J Transl Med
; 14(1): 198, 2016 07 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-27369977
15.
Clear Cell Renal Cell Carcinoma Subtypes Identified by BAP1 and PBRM1 Expression.
J Urol
; 195(1): 180-7, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26300218
16.
Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 14(4): 450-73, 2016 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-27059193
17.
NCCN Guidelines Insights: Melanoma, Version 3.2016.
J Natl Compr Canc Netw
; 14(8): 945-58, 2016 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-27496110
18.
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.
JAMA
; 315(15): 1600-9, 2016 Apr 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-27092830
19.
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial.
Lancet
; 384(9948): 1109-17, 2014 Sep 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-25034862
20.
Negative Sentinel Lymph Node Biopsy in Merkel Cell Carcinoma is Associated with a Low Risk of Same-Nodal-Basin Recurrences.
Ann Surg Oncol
; 22(12): 4060-6, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-25676844